Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting.

Hao SunHaizhou XingLijie HanYongping SongZhongxing JiangYanyan LiuJifeng Yu

Published in: Expert opinion on biological therapy (2024)

CD20×CD3 is the most widely studied BsAb, with promising results in patients with R/R DLBCL and R/R FL ≥ two prior lines of systemic therapy. Trials with the first line of B-cell lymphoma also revealed promising results. Hopefully, BsAb monotherapy or BsAb-containing regimens may become the standard therapy in patients with FL and DLBCL.

Keyphrases

diffuse large b cell lymphoma
single cell
randomized controlled trial
cancer therapy
stem cells
drug delivery
combination therapy
mesenchymal stem cells
study protocol
smoking cessation